JAK Inhibition Decreases the Autoimmune Burden in Down Syndrome

August 2024 in “ eLife ”

Angela L. Rachubinski, Elizabeth Wallace, Emily Gurnee, Belinda A Enriquez Estrada, Kayleigh R Worek, Keith P. Smith, Paula Araya, Katherine A. Waugh, Ross E. Granrath, Eleanor Britton, Hannah R. Lyford, Micah G. Donovan, Neetha Paul Eduthan, Amanda A. Hill, Barry Martin, Kelly D. Sullivan, Lina Patel, Deborah J. Fidler, Matthew D. Galbraith, Cory A. Dunnick, David A. Norris, Joaquı́n M. Espinosa

JAK inhibition tofacitinib alopecia areata psoriasis atopic dermatitis interferon cytokine autoantibodies Xeljanz

From the encyclopedia

Tofacitinib →

a JAK inhibitor for alopecia areata and other autoimmune conditions

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on elifesciences.org →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Janus Kinase Inhibitors for Alopecia Areata

7 citations , August 2023 in “Journal of the American Academy of Dermatology”

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata

32 citations , April 2019 in “JAAD case reports”

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.